Results 161 to 170 of about 25,638 (254)
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis
ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim +4 more
wiley +1 more source
Effects of liraglutide on gut bacterial community dynamics. [PDF]
Bull J, Durham PL, Mirza BS.
europepmc +1 more source
ABSTRACT Introduction Cardiovascular (CV) outcomes of Glucagon‐like peptide‐1 (GLP‐1)–based medicines among people with overweight and obese (OW/OB) population have been investigated by meta‐analyses of randomized controlled trials (RCTs), but an overall summary is lacking.
Muhammed Rashid +6 more
wiley +1 more source
Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity. [PDF]
Fernandes MT +4 more
europepmc +1 more source
ABSTRACT Introduction Pregnancy concurrent with incretin‐based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin‐based medications in relation to preconception, pregnancy, and postnatal health, and to propose ...
Kate Maslin +19 more
wiley +1 more source
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed +19 more
wiley +1 more source
Chronic social defeat stress induces a hypoglycemic shift and depression-related behaviors, both prevented by antidiabetic drugs. [PDF]
Qiu W +4 more
europepmc +1 more source
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Challenges and evidence in obesity guidelines. ABSTRACT Obesity remains a global health crisis characterized by substantial heterogeneity in diagnosis, management, and policy implementation. Although numerous national and international clinical practice guidelines have been published over the past decade, their translation into evidence‐based and ...
Rosero‐Revelo Ricardo +13 more
wiley +1 more source
Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis. [PDF]
Zhu K +6 more
europepmc +1 more source

